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See Article, pages 38–44Chronic hepatitis C virus (HCV) infection is a leading cause of
end-stage liver disease worldwide and results in complications,
such as decompensated cirrhosis and hepatocellular carcinoma.
However, large epidemiological studies have suggested that only
about half of all HCV infected patients show signiﬁcant ﬁbrosis
and only a fraction of these are at risk of developing end-stage
liver disease [1]. These large inter-individual differences in the
progression of HCV infection are partly due to exogenous factors
(e.g. alcohol intake, co-infections, diabetes) [2]. Nevertheless,
recent studies have demonstrated that ﬁbrosis development sig-
niﬁcantly depends on host genetic factors. In this respect, liver
ﬁbrosis is considered to be a complex genetic trait, in which mul-
tiple genes and their interactions contribute to the severity of
liver ﬁbrosis.
This hypothesis has been supported by multiple cross-sec-
tional case-control studies which were based on the a priori
hypothesis that the distribution of polymorphic alleles is differ-
ent between subjects with mild versus patients with severe ﬁbro-
sis. A major limitation of these studies was their lack of
reproducibility and the limited number of polymorphisms inves-
tigated within the respective cohorts [3]. The elucidation of the
genetic basis for liver ﬁbrosis was taken a step further by the ﬁrst
large-scale genetic screen in patients with HCV induced liver
ﬁbrosis in 2007 [4]. In this analysis more than 20,000 single poly-
morphisms were analyzed in two independent cohorts of
patients of Caucasian ethnicity in a genome-wide scan. The
genetic data were subsequently analyzed in depth and a genetic
score was calculated which predicted the presence of severe
ﬁbrosis in the investigated patients [4]. This gene signature was
termed the ‘‘cirrhosis risk score’’ (CRS) and consisted of single
nucleotide polymorphisms in seven different genes (AP3S2,
AQP2, AZIN1, DEGS1, STXBP5L, TLR4, and TRPM5). Such a combina-
tion of SNPs into a score has also been applied in studies on the
genetic basis of cholesterol levels and prostate cancer [5].
The validity and potential clinical applicability of the CRS was
subsequently validated in a cohort from Italy [6]. All of the
patients in this study had mild ﬁbrosis at initial biopsy but did
not undergo antiviral therapy due to various clinical reasons.Journal of Hepatology 20
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a second liver biopsy. Overall, 24.4% showed no histologic pro-
gression, while 75.6% progressed by at least one stage. In this
group 45.0% progressed by at least two stages, and 10.3% by more
than two stages. When the CRS was applied to this cohort, the
mean CRS values were signiﬁcantly higher in patients with ﬁbro-
sis progression compared with those without progression [6].
In the current issue of the Journal of Hepatology, the clinical
value of the CRS in predicting ﬁbrosis progression has now been
prospectively validated in two further cohorts of HCV infected
patients with minimal liver ﬁbrosis at baseline [7]. Although both
cohorts were signiﬁcantly smaller than the number of patients
investigated by Marcolongo et al. [6], the CRS was again signiﬁ-
cantly associated with ﬁbrosis progression in untreated patients
for a follow-up period of at least ﬁve years. These results suggest
that the CRS remains a prognostic marker even in relatively low
powered studies. An additional strength of the study by Trepo
et al. is that the CRS was also analyzed together with a recent
non-invasive ﬁbrosis staging score, the enhanced liver ﬁbrosis
(ELF) test [8]. This biomarker based score includes the serum lev-
els of hyaluronic acid, amino-terminal propeptide of type III col-
lagen (PNIIIP), and tissue inhibitor of matrix metalloproteinase 1
(TIMP1) and has been validated as a non-invasive marker of liver
ﬁbrosis in cross-sectional studies of different liver disease etiolo-
gies. Notably, this score has now been identiﬁed to predict histo-
logic ﬁbrosis progression in the study by Trepo et al. [7]. Since the
ELF score is a combination of matrix components and functional
inhibitors of their degradation, this new and interesting observa-
tion again underscores that ﬁbrosis is a dynamic process involv-
ing different aspects of matrix biology. Clinically, the association
of the ELF score with ﬁbrosis progression in HCV infection needs
conﬁrmation in larger cohorts, but might lead to new predictive
parameters in the future.
In a regression model, the CRS was associated with an OR of
2.23 for ﬁbrosis progression, an effect size which is low for com-
bined SNP scores but in the range of large-scale SNP analysis in
complex diseases [9]. In ROC analysis the combination of the
CRS with the ELF test together with readily available clinical
parameters (gender, alcohol consumption and presence of diabe-
tes) yielded an area under the curve of 0.87, which is better than
the predictive value of clinical parameters (AUC 0.74) or the CRS
(AUC 0.85) score alone [7]. These analyses indeed suggest that the11 vol. 55 j 3–4
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speciﬁcity and sensitivity of the combined markers are sufﬁcient
for predicting ﬁbrosis progression in clinical practice.
The ﬁndings by Trepo et al. stress the question whether there
is a clinical need for predicting ﬁbrosis progression in patients
with chronic HCV infection since some current guidelines [10]
recommend the treatment of almost all HCV-RNA positive
patients. Indeed, prediction of ﬁbrosis progression might be
reserved for subjects with relative contraindications to interferon
and ribavirin treatment (e.g. psychiatric disorders, hemoglobin
abnormalities, concurrent autoimmune diseases), patients who
failed to achieve a sustained virological response to current reg-
imens or who are candidates for clinical studies which assess
the utility of anti-ﬁbrotic treatments. However, these populations
represent a signiﬁcant number of individuals seen at specialised
centers and the CRS might help to personalise clinical care of
these individuals. Personalised decision making might even be
supplemented by genetic determination of the likelihood of treat-
ment response by genotyping the IL28B locus [11] and by estima-
tion of the risk for ribavirin induced anemia by ITPA variants [12].
However, with such genetic parameters on the horizon, the ques-
tion arises about how to deal with persons who carry the at-risk
alleles for ﬁbrosis progression, treatment failure, or anemia.
These aspects need to be thoroughly discussed with the affected
patients prior to starting antiviral therapy and a clinical consen-
sus needs to be established in the hepatologists community.
What other lessons can be drawn from the validated associa-
tion of the CRS with ﬁbrosis progression in HCV infection?
Despite the fact that all genes included into the score have now
been identiﬁed, only one (TLR4) has yet been functionally associ-
ated with liver ﬁbrosis in vitro and in vivo [13]. However, the
other genes of the CRS might also point to interesting molecular
pathways of ﬁbrogenesis, such as aquaporins which seem to be
implicated in chronic kidney injury [14]. According to this
hypothesis, we have learned from large-scale genetic association
studies in age-related macular degeneration and Crohn’s disease
that strong and reliable associations might lead to new molecular
driven concepts for these diseases. This has already led to the ﬁrst
clinical trials in age-related macular degeneration by blocking the
complement pathway [15], although a few years ago the involve-
ment of this inﬂammatory pathway in the disease had not even
been suspected. Thus, it remains a great scientiﬁc challenge to
further elucidate the functional importance of the genes involved
in the CRS with regards to ﬁbrogenesis in HCV infection. Based on
this knowledge new interventional anti-ﬁbrotic strategies for
patients who fail to respond to current or future antiviral thera-
pies might be developed. In such studies the CRS might guide
the selection of patients who would most beneﬁt from anti-ﬁbro-
tic therapies. Furthermore, the CRS should be tested in other
ﬁbrotic liver diseases (including alcoholic, NASH, or biliary dis-
ease) in order to better understand the predictive and pathophys-
iological impact of this score and its genes across different
etiologies.4 Journal of Hepatology 2Conﬂict of interest
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